

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssseptal64lcxc

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 AUG 15 CAOLD to be discontinued on December 31, 2008  
NEWS 3 OCT 07 EFFULL enhanced with full implementation of EPC2000  
NEWS 4 OCT 07 Multiple databases enhanced for more flexible patent  
number searching  
NEWS 5 OCT 22 Current-awareness alert (SDI) setup and editing  
enhanced  
NEWS 6 OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT  
Applications  
NEWS 7 OCT 24 CHEMLIST enhanced with intermediate list of  
pre-registered REACH substances  
NEWS 8 NOV 21 CAS patent coverage to include exemplified prophetic  
substances identified in English-, French-, German-,  
and Japanese-language basic patents from 2004-present  
NEWS 9 NOV 26 MARPAT enhanced with FSORT command  
NEWS 10 NOV 26 MEDLINE year-end processing temporarily halts  
availability of new fully-indexed citations  
NEWS 11 NOV 26 CHEMSAFE now available on STN Easy  
NEWS 12 NOV 26 Two new SET commands increase convenience of STN  
searching  
NEWS 13 DEC 01 ChemPort single article sales feature unavailable  
NEWS 14 DEC 12 GBFULL now offers single source for full-text  
coverage of complete UK patent families  
  
NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 08:06:48 ON 15 DEC 2008

=> file .meeting

'EVENTLINE' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):ignore

'IMSDRUGCONF' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):ignore

'MEDICONF' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):ignore

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'AGRICOLA' ENTERED AT 08:07:09 ON 15 DEC 2008

FILE 'BIOTECHNO' ENTERED AT 08:07:09 ON 15 DEC 2008

COPYRIGHT (C) 2008 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CONFSCI' ENTERED AT 08:07:09 ON 15 DEC 2008

COPYRIGHT (C) 2008 Cambridge Scientific Abstracts (CSA)

FILE 'HEALSAFE' ENTERED AT 08:07:09 ON 15 DEC 2008

COPYRIGHT (C) 2008 Cambridge Scientific Abstracts (CSA)

FILE 'LIFESCI' ENTERED AT 08:07:09 ON 15 DEC 2008

COPYRIGHT (C) 2008 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 08:07:09 ON 15 DEC 2008

Any reproduction or dissemination in part or in full, by means of any process and on any support whatsoever is prohibited without the prior written agreement of INIST-CNRS. COPYRIGHT (C) 2008 INIST-CNRS. All rights reserved.

=> mixed(6A) (antagonist) (3A) (agonist) (10A) (IC50)

L1	0 FILE AGRICOLA
L2	0 FILE BIOTECHNO
L3	0 FILE CONFSCI
L4	0 FILE HEALSAFE
L5	0 FILE LIFESCI
L6	0 FILE PASCAL

TOTAL FOR ALL FILES

L7 0 MIXED(6A) (ANTAGONIST) (3A) (AGONIST) (10A) (IC50)

=> mixed and (antagonist) and (agonist) and (IC50)

L8	1 FILE AGRICOLA
L9	0 FILE BIOTECHNO
L10	0 FILE CONFSCI
L11	0 FILE HEALSAFE
L12	1 FILE LIFESCI

L13 1 FILE PASCAL

TOTAL FOR ALL FILES

L14 3 MIXED AND (ANTAGONIST) AND (AGONIST) AND (IC50)

=> dup rem

ENTER L# LIST OR (END):114

PROCESSING COMPLETED FOR L14

L15 3 DUP REM L14 (0 DUPLICATES REMOVED)

=> d 115 ibib abs total

L15 ANSWER 1 OF 3 AGRICOLA Compiled and distributed by the National  
Agricultural Library of the Department of Agriculture of the United States  
of America. It contains copyrighted materials. All rights reserved.  
(2008) on STN

ACCESSION NUMBER: 2004:16549 AGRICOLA

DOCUMENT NUMBER: IND43622383

TITLE: Black cohosh acts as a mixed competitive  
ligand and partial agonist of the serotonin  
receptor.

AUTHOR(S): Burdette, J.E.; Liu, J.; Chen, S.N.; Fabricant, D.S.;  
Piersen, C.E.; Barker, E.L.; Pezzuto, J.M.; Mesecar,  
A.; Van Breemen, R.B.; Farnsworth, N.R.  
DNAL (381 J8223)

AVAILABILITY: Journal of agricultural and food chemistry, 2003 Sept.  
SOURCE: 10 Vol. 51, no. 19 p. 5661-5670  
ISSN: 0021-8561

NOTE: Includes references

DOCUMENT TYPE: Article

FILE SEGMENT: Other US

LANGUAGE: English

AB Extracts of the rhizome of black cohosh [*Actaea racemosa* L., formerly  
called *Cimicifuga racemosa* (L.) Nutt.] were evaluated for potential  
mechanisms of action in the alleviation of menopausal hot flashes.  
Ovariectomized Sprague-Dawley rats were administered a 40% 2-propanol  
extract of black cohosh [4, 40, and 400 mg/(kg day)] by gavage for 2 weeks  
with or without estradiol [50 micrograms/(kg day)] to determine if black  
cohosh could act as an estrogen or antiestrogen on the basis of an  
increase in uterine weight or vaginal cellular cornification. No effects  
were observed on uterine weight or on vaginal cellular cornification in  
rats treated with black cohosh alone or in combination with  
17(beta)-estradiol, indicating this black cohosh extract had no estrogenic  
or antiestrogenic properties in the ovariectomized rat model. To evaluate  
other potential pathways by which black cohosh might reduce menopausal hot  
flashes, serotonin activity was first assessed by the inhibition of  
radioligand binding to cell membrane preparations containing recombinant  
human serotonin receptor (5-HT) subtypes. A 40% 2-propanol extract of  
black cohosh was tested against 10 subtypes of the serotonin receptor,  
revealing the presence of compounds with strong binding to the 5-HT1A,  
5-HT1D, and 5-HT7 subtypes. Subsequent binding studies were carried out  
using 5-HT1A and 5-HT7 receptors because of their association with the  
hypothalamus, which has been implicated in the generation of hot flashes.  
The black cohosh 40% 2-propanol extract inhibited [3H]lysergic acid  
diethylamide (LSD) binding to the human 5-HT7 receptor (IC50 =  
2.4 (+/-) 0.4 micrograms/mL) with greater potency than binding of  
[3H]-8-hydroxy-2-(di-N-propylamino)tetralin to the rat 5-HT1A receptor (  
IC50 = 13.9 (+/-) 0.6 micrograms/mL). Analysis of ligand binding  
data indicated that components of a black cohosh methanol extract  
functioned as a mixed competitive ligand of the 5-HT7 receptor.  
In addition, a black cohosh methanol extract elevated cAMP levels in

293T-5-HT7-transfected HEK cells, suggesting the extract acted as a partial agonist at the receptor. The elevation in cAMP mediated by the black cohosh extract could be reversed in the presence of the antagonist methiothepin, indicating a receptor-mediated process. These data suggest that reductions in hot flashes in some women taking black cohosh may not be due to estrogenic properties. This study identifies other possible biological targets of black cohosh that could account for reported biological effects.

L15 ANSWER 2 OF 3 PASCAL COPYRIGHT 2008 INIST-CNRS. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 1994-0077466 PASCAL  
 COPYRIGHT NOTICE: Copyright .COPYRGT. 1994 INIST-CNRS. All rights reserved.  
 TITLE (IN ENGLISH): In vitro inhibition of cellular immune responses by benzodiazepines and PK 11195: effects on mitogen- and alloantigen-driven lymphocyte proliferation and on IL-1, IL-2 synthesis and IL-2 receptor expression  
 AUTHOR: RAMSEIER H.; LICHTENSTEIGER W.; SCHLUMPF M.  
 CORPORATE SOURCE: Univ. Zuerich, inst. immunology virology, Zuerich, Switzerland  
 SOURCE: Immunopharmacology and immunotoxicology, (1993), 15(5), 557-582, 40 refs.  
 ISSN: 0892-3973  
 DOCUMENT TYPE: Journal  
 BIBLIOGRAPHIC LEVEL: Analytic  
 COUNTRY: United States  
 LANGUAGE: English  
 AVAILABILITY: INIST-18382, 354000023793460040

AN 1994-0077466 PASCAL  
 CP Copyright .COPYRGT. 1994 INIST-CNRS. All rights reserved.  
 AB In vitro mitogen-driven lymphocyte proliferation tests (Con A, LPS) on murine lymph node and spleen cells revealed inhibition of T and B cell stimulation by different benzodiazepines and by PK 11195, with IC50 values in the low micromolar range. T cell responses as a consequence of recognition of alloantigens, as measured in mixed lymphocyte cultures (MLC), were affected in an analogous way. In all systems, agonists at peripheral type benzodiazepine receptors (Ro 5-4864 and the non-benzodiazepine compound PK 11195) and diazepam which acts on both, central and peripheral type benzodiazepine receptors, were most potent; clonazepam, a central type agonist, proved about half as active. The central type antagonist Ro 15-1788 failed to antagonize the action of diazepam and clonazepam

L15 ANSWER 3 OF 3 LIFESCI COPYRIGHT 2008 CSA on STN  
 ACCESSION NUMBER: 84:97738 LIFESCI  
 TITLE: Regulation of opioid antagonist and mu, kappa or delta agonist binding by guanine nucleotide and sodium.  
 AUTHOR: Ishizuka, Y.; Oka, T.  
 CORPORATE SOURCE: Dep. Pharmacol., Sch. Med., Tokai Univ., Isehara 259-11, Japan  
 SOURCE: JAP. J. PHARMACOL., (1984) vol. 36, no. 3, pp. 397-405.  
 DOCUMENT TYPE: Journal  
 FILE SEGMENT: N3; M  
 LANGUAGE: English  
 SUMMARY LANGUAGE: English  
 AB Effects of 5'-guanylylimidodiphosphate (Gpp(NH)p) and sodium on the inhibition by various opioids of ( super(3)H)-naloxone binding to guinea-pig brain membrane preparations were studied. The ratio of the concentration required to produce a 50% inhibition of (

super(3)H)-naloxone binding in the presence of both Gpp(NH)p and sodium to that in the absence of both GPP(NH)p and sodium was less than 1 for antagonists, from 3 to 10 for mixed agonist-antagonists, from 16 to 85 for either kappa, delta, or peptide mu agonists, and more than 200 for morphine-like non-peptide mu agonists. Exceptionally, the IC50 ratio of N,N-diallyl-(D-Ala super(2), D-Leu super(5))-enkephalin, an opioid which had been shown not to have an agonist activity in guinea-pig ileum but to have a naloxone-reversible agonist activity in mouse vas deferens, was less than 1. The significance of the different IC50 ratio among opioids employed in the present study was discussed.